STERIS plc

(New York Stock Exchange)

STERIS (STE) stock at a glance

Full STERIS report
Ticker
STE
Exchange
New York Stock Exchange
News sentiment Β· last 30 days
+53 Bullish
30-day average of 4 articles Β· scale βˆ’100 to +100

Across 4 scored articles from Oct 16 to Nov 14, 2026 (UTC), the average sentiment of STERIS news is Bullish (+53) on a scale from βˆ’100 to +100.

+55 Bullish 1 article

Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.

Articles

27
Show Summary
Show Bulletpoints
Detailed View
Neutral 0

STERIS to Host a Conference Call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026

AI-generated analysis

STERIS plc (NYSE: STE), based in Dublin, Ireland, announced today it will host a conference call to discuss its fiscal 2026 fourth quarter and full year results on May 12, 2026. The event is scheduled for 9:00 a.m. ET and will be accessible live via the web at www.steris-ir.com or by telephone at 1-833-535-2199 in the United States or 1-412-902-6776 internationally. Investors wishing to participate must ask to join the conference call for STERIS plc when dialing the international number. A comprehensive press release detailing the financial results will be issued following the close of U.S. markets on May 11, 2026. For those who cannot attend the live broadcast, a replay of the conference call will be available starting at 12:00 p.m. ET on May 12, 2026. Replays can be accessed via telephone by dialing 1-855-669-9658 in the U.S. or 1-412-317-0088 internationally, along with access code 3141167, or through the company's investor relations website at www.steris-ir.com. STERIS describes itself as a leading global provider of products and services supporting patient care, emphasizing infection prevention to help customers create a healthier and safer world through innovative healthcare and life science solutions worldwide. The announcement includes a standard cautionary statement regarding forward-looking information under the Private Securities Litigation Reform Act of 1995. The company identified numerous factors that could cause actual results to differ materially from expectations, including operating costs and pricing pressures related to inflation, difficulties integrating acquired businesses, changes in tax laws or trade barriers, and regulatory actions such as the Isomedix litigation. Additional risks cited include international unrest, currency fluctuations, delays in order receipt or shipment, failure to achieve anticipated benefits from acquisitions, indebtedness levels, credit availability issues, industry competition, labor-related disruptions, and potential economic downturns or recessions.

πŸ“… STERIS will report Fiscal 2026 Q4 results after U.S. market close on May 11, 2026.

⏰ Live conference call scheduled for May 12, 2026 at 9:00 a.m. ET with replay available.

⚠ Management highlighted inflation risks, integration challenges, and litigation as key financial uncertainties ahead of results.

πŸ“… STERIS announced a conference call for Fiscal 2026 fourth quarter and full year results on May 12, 2026.

⏰ The call is scheduled to begin at 9:00 a.m. ET and will discuss financial performance metrics.

🌐 A press release detailing the results will be issued after U.S. market closes on May 11, 2026.

πŸ“ž Investors can join live via phone (1-833-535-2199 in US) or online at www.steris-ir.com.

⏳ A replay of the call will be available starting at 12:00 p.m. ET on May 12, 2026.

πŸ”‘ The access code for the call and replay is 3141167 via specific dial-in numbers.

πŸ₯ STERIS operates as a global provider of infection prevention and healthcare products.

⚠️ The company included standard forward-looking statements regarding future trends and expectations.

πŸ“‰ Potential risks cited include operating cost pressures, inflation impacts, and margin erosion.

πŸ›‘οΈ Integration challenges from acquired businesses may lead to unknown liabilities or integration difficulties.

πŸ’Έ Changes in tax laws or tariffs could increase consolidated tax liabilities for the company.

βš–οΈ Legal issues, specifically mentioning Isomedix litigation, could delay product introductions or affect production.

🌍 International unrest, military conflicts, and currency fluctuations are listed as potential performance impacts.

πŸ“‰ Competition in the industry may exert pricing pressure and decrease demand for products.

πŸ‘₯ Labor-related disruptions, such as strikes or union negotiations, pose operational risks.

πŸ—οΈ Financial results may not achieve anticipated growth synergies from acquisitions or restructuring efforts.

Bullish Signals
  • STERIS is a leading global healthcare and life sciences provider focused on infection prevention.
  • Company will host a Fiscal 2026 Q4 and Full Year Results conference call on May 12, 2026.
Risk Factors
  • Operating cost pressures threaten profit margins.
  • Acquisition synergies may not materialize as planned.
  • Isomedix litigation risks delaying product launches.
  • Order delays could disrupt manufacturing and shipments.
  • Competition may pressure pricing and reduce demand.
  • Tax law changes could increase liabilities.
  • Integration of acquired businesses faces unknown risks.
  • Global instability threatens operations and results.
  • Indebtedness limits flexibility and increases costs.
  • Labor disputes could adversely affect performance.
Bullish Signals
  • STERIS is a leading global provider of products and services supporting patient care with an emphasis on infection prevention, demonstrating strong positioning in healthcare and life sciences. The company will host a conference call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026, indicating scheduled delivery of upcoming financial performance data to investors.
Risk Factors
  • STERIS faces significant risks from operating cost pressures and pricing constraints, which could lead to erosion of profit margins if these challenges materialize.
  • The company may struggle to realize anticipated growth, productivity improvements, cost savings, and synergies from acquisitions or divestitures as planned.
  • Steris has identified the Isomedix litigation as a potential risk that could delay new product introductions, impact production or marketing, and result in uncovered costs.
  • Operating uncertainties include the possibility of order delays, cancellations, or disruptions in manufacturing and shipment of ordered products.
  • Increasing competition within the industry may exert downward pressure on STERIS's pricing strategy and reduce demand for its products and services.
  • Changes in tax laws, interpretations, or adoption of income tax treaties could increase consolidated tax liabilities and impact financial performance.
  • Steris's ability to successfully integrate acquired businesses is at risk due to potential unknown liabilities, impairments, or higher-than-expected integration costs.
  • International unrest, military conflicts, economic downturns, currency fluctuations, and trade barriers pose threats to operations and financial results.
  • The company's indebtedness limits financial flexibility and may increase future borrowing costs under adverse market conditions.
  • Labor-related issues such as strikes, unsuccessful union negotiations, or workforce disruptions could adversely affect operations and performance.
Slightly Bullish +25

Surgical Equipment & Consumables - Diversified Stocks Q4 Earnings: STERIS (NYSE:STE) Firing on All Cylinders

AI-generated analysis

The article reviews Q4 earnings results for five major surgical equipment and consumables diversified stocks, noting that the industry group collectively reported slower growth with revenues missing analysts' consensus estimates by 1.5%. Following these results, average share prices for the sector have declined approximately 8%. The text outlines industry dynamics where consistent demand driven by aging populations and recurring revenue is offset by high R&D costs, regulatory pressures, and pricing constraints from cost-conscious customers. STERIS reported Q4 revenues of $1.50 billion, a 9.2% year-over-year increase that exceeded analysts' expectations by 1.1%. Despite this top-line beat, the quarter was characterized as mixed due to the narrow revenue beat, leading the stock to fall 14.8% since reporting and trade at $225.79. Solventum reported revenues of $2.00 billion, down 3.7%, which still outperformed analyst expectations by 1.9%; however, it missed EPS estimates significantly, causing its stock to decline 8.4% to a price of $70.48 despite having the largest revenue beat among its peers. Becton Dickinson posted revenues of $4.49 billion, up 3.5%, but fell short of analyst expectations by 12.8% after missing both full-year EPS guidance and revenue estimates. This weak performance relative to analysts resulted in its stock dropping 23.3% to trade at $161.04. In contrast, Zimmer Biomet achieved the fastest revenue growth among its peers with revenues of $2.24 billion, up 10.9%, beating analyst expectations by 0.9%. While it also narrowly missed full-year EPS guidance, the stock remains resilient, trading up 6.8% at $95.82. CONMED reported revenues of $373.2 million, up 7.9%, topping revenue estimates by 1.7%, but significantly missed full-year earnings and revenue guidance; consequently, its stock only rose 1.1% to trade at $39.10. The article concludes with an unrelated narrative shift from late 2025 through early 2026 regarding market sentiment toward artificial intelligence and geopolitical risk. It describes how initial fears about AI eroding pricing power led investors to rotate into safer havens, only for the market focus to abruptly shift in spring 2026 from technological disruption to geopolitical tensions, specifically noting the US conflict with Iran as a dominant driver of market psychology by late 2025.

πŸ“Š Five major surgical equipment stocks collectively missed Q4 revenue estimates by 1.5%.

πŸ“‰ Four of five companies faced significant stock declines after earnings reports released.

πŸ”¬ Zimmer Biomet is the sole standout, rising 6.8% on strong revenue growth.

🦠 STERIS (NYSE:STE) reported Q4 revenues of $1.50 billion, representing a 9.2% year-over-year increase that beat analyst expectations by 1.1%.

πŸ“‰ Despite the revenue beat, STERIS shares have dropped 14.8% since reporting and currently trade at $225.79.

πŸ₯ The surgical equipment industry benefits from consistent demand driven by aging populations and recurring consumable revenue.

⚠️ Industry headwinds include high R&D costs, regulatory compliance expenses, intense competition, and pressure to reduce healthcare costs.

πŸ’‘ Future tailwinds for the sector involve the integration of AI and robotics into surgical procedures.

πŸ“Š As a group, the five tracked surgical equipment stocks missed analysts' consensus revenue estimates by 1.5% in Q4.

πŸ“‰ On average, the shares of these five companies have declined by 8% since the latest earnings results.

πŸ”¬ Solventum (NYSE:SOLV) reported $2.00 billion in revenue, a 3.7% year-over-year decrease that still beat analysts' expectations by 1.9%.

πŸ“‰ Solventum's stock is down 8.4% since reporting and trades at $70.48 despite beating organic revenue estimates.

⚠️ Solventum delivered the biggest analyst estimates beat but missed its EPS estimates significantly.

πŸ”¬ Becton Dickinson (NYSE:BDX) reported $4.49 billion in revenue, up 3.5% year-over-year but fell short of expectations by 12.8%.

πŸ“‰ BD's stock has plummeted 23.3% since results and trades at $161.04 due to missing full-year EPS guidance.

🦴 Zimmer Biomet (NYSE:ZBH) achieved the fastest revenue growth in the peer group with a 10.9% year-over-year increase to $2.24 billion.

πŸ“ˆ Zimmer Biomet's stock is the only one up, rising 6.8% since reporting and currently trading at $95.82.

πŸ”¬ Zimmer Biomet beat revenue estimates by 0.9% but slightly missed its full-year EPS guidance estimates.

βš•οΈ CONMED (NYSE:CNMD) reported $373.2 million in revenue, up 7.9% year-over-year, topping analysts' expectations by 1.7%.

πŸ“‰ CONMED faces challenges as it significantly missed full-year EPS guidance and failed to meet revenue expectations.

πŸ“ˆ The stock is up 1.1% since reporting and trades at $39.10 despite missing its broader annual guidance.

Bullish Signals
  • STERIS (NYSE:STE) reported Q4 revenues of $1.50 billion, representing a 9.2% year-on-year increase that exceeded analysts' expectations by 1.1%.
  • The company's growth is supported by tailwinds such as an aging population requiring more surgical interventions and the increasing integration of AI and robotics for innovation.
  • Solventum (NYSE:SOLV) delivered the biggest analyst estimates beat among its peers with organic revenue growing despite a broader industry slowdown.
  • Zimmer Biomet (NYSE:ZBH) achieved the fastest revenue growth among its tracked peers, posting revenues of $2.24 billion up 10.9% year-on-year and beating estimates by 0.9%.
  • Notably, Zimmer Biomet's stock is up 6.8% since reporting results, demonstrating strong market confidence in its orthopedic and robotic technologies.
  • CONMED (NYSE:CNMD) reported revenues of $373.2 million, a 7.9% year-on-year increase that topped analysts' expectations by 1.7%.
  • The broader surgical equipment industry benefits from consistent demand driven by recurring consumable revenue and long-term contracts with healthcare providers.
Risk Factors
  • The group of five tracked surgical equipment & consumables stocks reported a slower Q4, with combined revenues missing analysts' consensus estimates by 1.5%.
  • On average, share prices for these companies have declined 8% since the latest earnings results, indicating investor dissatisfaction despite mixed top-line results.
  • STERIS (NYSE:STE) stock is down 14.8% since reporting, currently trading at $225.79, despite a revenue beat that was narrow.
  • Solventum (NYSE:SOLV) recorded a significant miss of analysts' EPS estimates and saw its stock drop 8.4% to trade at $70.48.
  • Becton Dickinson (NYSE:BDX) significantly missed both analysts' full-year EPS guidance and revenue estimates by 12.8%, causing its stock to fall 23.3% to $161.04.
  • The industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and widespread efforts to reduce healthcare costs which may constrain profitability.
  • High costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, continue to threaten the sector's margins.
Very Bullish +80

Steris PLC stock outperforms competitors on strong trading day

AI-generated analysis

Steris PLC (STE) shares rose 1.87% to $223.55 on Wednesday, April 22, 2026, outperforming broader market indices as the S&P 500 climbed 1.05% to 7,137.90 and the Dow Jones Industrial Average gained 0.69% to 49,490.03. Despite this positive trading session, STE remains 17.03% below its 52-week high of $269.44, a peak reached on January 16. The stock's performance occurred within an all-around favorable market environment, though specific company-driven catalysts for the outperformance were not detailed in the report. MarketWatch provided the data based on intraday feeds from FACTSET and Nasdaq reports, noting that real-time quotes reflect trades reported through Nasdaq only with potential delays of at least 15 minutes per exchange requirements.

πŸ“ˆ Steris shares rose 1.87% to $223.55.

πŸ† S&P 500 climbed 1.05% to 7,137.90.

πŸ“‰ Dow Jones gained 0.69% to 49,490.03.

🎯 Stock remains 17.03% below its 52-week high.

- πŸ“ˆ Steris PLC shares rose 1.87% to $223.55 on Wednesday.

- πŸ† The S&P 500 Index climbed 1.05% to reach 7,137.90.

- πŸ“‰ Dow Jones Industrial Average gained 0.69% to hit 49,490.03.

- 🎯 Stock closed 17.03% below its 52-week high of $269.44.

- πŸ—“οΈ The previous record high was set on January 16th.

Bullish Signals
  • Shares rose 1.87% to $223.55.
  • Stock outperformed competitors in favorable session.
Bullish Signals
  • Shares of Steris PLC rose 1.87% to $223.55 on Wednesday.
  • Steris PLC stock outperformed competitors during a favorable trading session.
Somewhat Bullish +45

Is There Now An Opportunity In STERIS plc (NYSE:STE)? - simplywall.st

AI-generated analysis

STERIS plc (NYSE:STE) has experienced significant price volatility, trading between $212 and $269 recently, with the current price around $221. Simply Wall St's valuation model suggests the stock is fairly priced at approximately 6.4% below its intrinsic value of $236.20, indicating a reasonable entry point but limited immediate upside potential based on current metrics. The article highlights STERIS's optimistic future growth outlook, projecting profit increases of 43% over the next couple of years. This expected growth is anticipated to drive higher cash flows and potentially lead to an increased share valuation in the future, supported by the company's solid track record and excellent balance sheet. While the positive growth trajectory is encouraging, the current trading price around fair value suggests that now may not be the optimal time for new investors to enter. The analysis advises potential buyers to monitor the stock for a price drop below its fair value or to investigate other fundamental factors like management track record and balance sheet strength before committing capital.

πŸ“‰ Shares volatile between $212 and $269 recently.

πŸ’° Current price $221 is 6.4% below intrinsic value.

πŸš€ Analysts forecast 43% profit growth over two years.

βš–οΈ Company holds a solid track record and balance sheet.

πŸ“Š Fair value pricing may not be optimal entry point.

πŸ“‰ STERIS shares have been volatile, ranging from a low of $212 to a high of $269 in recent months.

πŸ’° The current trading price of approximately $221 is valued at 6.4% below the calculated intrinsic value of $236.20.

πŸš€ Analyst forecasts project a significant 43% profit growth over the next two years.

πŸ’΅ Higher future profits are expected to feed into an increased share valuation for STERIS.

βš–οΈ The company maintains a solid track record and an excellent balance sheet.

πŸ“Š Simply Wall St notes that current fair value pricing may not be the optimal entry point for new investors.

Bullish Signals
  • Projected 43% profit growth over next couple of years.
  • Solid track record and excellent balance sheet ensure stability.
  • Higher future cash flows could increase share valuation.
  • High beta indicates potential for significant price movement.
Risk Factors
  • Price at fair value limits immediate upside.
  • High volatility and beta cause unpredictable swings.
Bullish Signals
  • STERIS is projected to see profit growth of 43% over the next couple of years, indicating strong future performance.
  • The company possesses a solid track record and an excellent balance sheet, providing financial stability.
  • Higher expected cash flows from future growth could lead to an increased share valuation.
  • The stock's high beta indicates potential for significant price movement relative to the broader market.
Risk Factors
  • The current share price is trading around its fair value, suggesting limited immediate upside potential for new buyers.
  • High volatility and a high beta mean the stock could sink lower or rise higher unpredictably in the near term.
Neutral 0

Steris Plc (NYSE:STE) Expands Healthcare Sterilization Capabilities Global Markets S&P 500

AI-generated analysis

Steris Plc (NYSE:STE) is a leading company within the healthcare equipment and services sector, specializing in providing solutions for infection prevention, contamination control, and clinical efficiency. The latest news indicates that Steris is expanding its capabilities specifically in healthcare sterilization, though specific details regarding the scope or financial metrics of this expansion are not provided in the available text due to content restrictions on the source article. The provided information appears to be a snippet from a broader market update dated March 19, 2026, which also features other companies such as Transocean (NYSE:RIG), Gray Media (NYSE:GTN), AstraZeneca (NYSE:AZN), and Teleflex (NYSE:TFX) achieving various market milestones. However, the detailed article content for Steris is gated behind a login or sign-up wall requiring user confirmation with Kalkine Media to access full text. Consequently, specific data points, quotes from executives, or direct implications for investors regarding the sterilization expansion are not available in this summary beyond the company name, sector classification, and headline focus on global market capabilities. Access to the full report would likely provide a more comprehensive view of Steris Plc's strategic growth, financial performance, and specific operational details related to its S&P 500 status. Without access to the full text behind the login requirements presented in the source content, no further specific numbers or definitive quotes can be accurately included while strictly adhering to the rule against speculation or adding external information not found in the provided article snippet.

πŸ”¬ Steris expands global healthcare sterilization capabilities.

πŸ₯ Company operates in healthcare equipment and services.

πŸ›‘οΈ Focuses on infection prevention and clinical efficiency.

πŸ”¬ Steris Plc (NYSE:STE) is expanding its healthcare sterilization capabilities to serve global markets.

πŸ₯ The company operates within the healthcare equipment and services sector.

πŸ›‘οΈ It provides specialized solutions focused on infection prevention, contamination control, and clinical efficiency.

Bullish Signals
  • STERIS plc (NYSE:STE) is expanding its healthcare sterilization capabilities, signaling strategic growth in infection prevention and contamination control markets.
  • The company operates within the healthcare equipment and services sector, delivering specialized solutions that support clinical efficiency.
Risk Factors
  • The article content is restricted behind a login wall, limiting the ability to assess Steris plc (NYSE:STE)'s actual financial performance or operational risks.
  • No specific negative metrics, financial data, or risk factors are disclosed in the provided text about Steris Plc.
Somewhat Bullish +50

A Look At STERIS (STE) Valuation After Recent Share Price Weakness

AI-generated analysis

STERIS Inc (STE) has recently experienced a decline in share performance, with the stock dropping approximately 14% over the past month and 15% over the past three months. Despite this recent weakness, the company continues to report revenue and net income growth. As of the latest data, STE is trading at $214.57, which marks a 1-day return of 1.05%, a 30-day return of 13.60%, and a one-year total shareholder return of 4.87%. This recent pullback contrasts with a positive multi-year outcome and suggests the stock is currently trading below certain valuation estimates. Simply Wall St's analysis indicates that STERIS is valued at a discount to its estimated fair value, which stands at $281.25. This fair value is derived using steady growth assumptions and a relatively low discount rate of 7.89%. The positive valuation narrative is supported by the continued expansion of STERIS's consumables and services segments, which generate high recurring revenue and offer margin visibility. This positioning allows the company to benefit from increasing healthcare expenditures and the adoption of best practice infection control standards, supporting both revenue and margin expansion in the future. However, investors are advised to consider several pressure points that could impact the stock, including tariff-related cost risks and ongoing healthcare reimbursement pressures that may weigh on margins. While the current price-to-earnings ratio is 29.7x, this is slightly higher than both the US Medical Equipment industry average of 28.1x and the peer average of 27.2x. The model suggests the market could potentially move toward a fair P/E ratio of 30.1x, raising questions about whether investors are overpaying today or underestimating the duration of such premiums. The article notes that while the company appears undervalued based on fundamental analysis and recurring revenue growth, it remains important for investors to evaluate key risks before making decisions.

πŸ“‰ Stock down 15% short-term despite recent price recovery to $214.57.

πŸ’° Undervalued by 23.6% with fair value estimated at $281.25.

βš–οΈ Growth in consumables supports margins amid tariff and reimbursement risks.

πŸ“‰ STERIS (STE) shares have declined 14% over the past month and 15% over the past three months, contrasting with ongoing revenue and net income growth.

πŸ’° The stock currently trades at $214.57, representing a 1-day return of 1.05% and a 30-day recovery of 13.60% from recent lows.

πŸ“Š Long-term investors are noting a 4.87% total shareholder return over the past year despite short-term weakness.

βš–οΈ Simply Wall St analysis values STE at a fair price of $281.25, suggesting the stock is currently undervalued by approximately 23.6%.

πŸ’‘ The valuation model relies on steady growth assumptions and a low discount rate of 7.89%.

πŸ”¬ Continued expansion in consumables and services segments supports recurring revenue and margin visibility.

⚠️ Potential headwinds include tariff-related cost risks and ongoing healthcare reimbursement pressures that could impact margins.

πŸ“ˆ Current P/E ratio of 29.7x is slightly higher than the US Medical Equipment industry average of 28.1x and peer average of 27.2x.

🎯 Fair valuation models suggest the market multiple could stabilize around 30.1x over time.

πŸ’Ό The analysis highlights recurring revenue streams as a key driver behind the optimistic fair value forecast.

πŸ“‰ Investors are weighing whether the discount represents an attractive entry point or if expectations are already reflected in the price.

πŸ” Simply Wall St emphasizes that this analysis is based on historical data and forecasts, not financial advice.

🚫 The company has no position in STERIS and maintains an unbiased methodology for its valuations.

Bullish Signals
  • STERIS (STE) is currently trading at $214.57, which represents a significant discount to its fair value estimate of $281.25 according to analyst models.
  • The company demonstrates continued growth in both revenue and net income despite recent share price weakness, indicating potential for upside potential.
  • Expansion in consumables and services segments provides high recurring revenue and margin visibility, positioning STERIS to benefit from increasing healthcare expenditures.
  • Fair value calculations utilize steady growth assumptions and a relatively low discount rate of 7.89%, supporting a target upside based on valuation metrics.
  • The current P/E ratio of 29.7x is close to the model-suggested fair ratio of 30.1x, suggesting the market may move toward a premium multiple consistent with high quality fundamentals.
  • Recent trading activity shows positive momentum with a 1 day share price return of 1.05% and a 30 day return of 13.60%, offsetting longer-term weakness.
Risk Factors
  • The stock has underperformed significantly in the short term, down approximately 14% over the past month and 15% over the past 3 months.
  • Ongoing tariff-related cost risks and healthcare reimbursement pressures could weigh on profit margins despite revenue growth.
  • STERIS is currently trading at a P/E ratio of 29.7x, which exceeds the US Medical Equipment industry average of 28.1x and peer average of 27.2x.
  • The current stock price of $214.57 remains significantly below the fair value estimate of $281.25, suggesting valuation models rely on steady growth assumptions that may not hold if market conditions change.
  • Recent share price weakness contrasts with positive multi-year returns, creating potential confusion around future growth expectations.
Slightly Bullish +25

Is STERIS Stock Underperforming the Nasdaq?

AI-generated analysis

Mentor, Ohio-based STERIS plc (STE) is a large-cap stock valued at $21 billion that specializes in infection prevention products and services within the medical devices industry. The company offers a diverse mix of sterilizers, washers, surgical equipment, lights, and endoscopy accessories, positioning it as a one-stop solution for healthcare providers through its combination of consumables and capital equipment. Despite its market dominance and strong financial fundamentals, recent performance metrics indicate that STE has been underperforming broader market indices like the Nasdaq Composite during the current quarter. STE stock slipped 20.4% from its 52-week high of $269.44, reached on Jan. 16, with a more pronounced decline over the past three months compared to the Nasdaq. The shares have fallen 14.8% in the last quarter against a 4.7% loss for the Nasdaq Composite, dropped 14.1% over six months while the market lost less, and gained 27.8% annually versus STE's 3.5% drop year-to-date. Technical indicators suggest a bearish trend, with shares trading below both the 200-day moving average since early March and the 50-day moving average since early February. Despite these price declines, recent quarterly results on Feb. 4 showed positive financial outcomes. STERIS reported Q3 revenue of $1.50 billion, which exceeded analyst estimates of $1.48 billion, while adjusted earnings per share of $2.53 met Wall Street forecasts. A key rival, Stryker Corporation (SYK), has also struggled recently with 7.4% declines year-to-date and outpaced STE's losses on a six-month basis. Wall Street analysts maintain a "Moderate Buy" consensus rating for STERIS among nine covering firms, citing a mean price target of $288.43 that suggests approximately 34.4% potential upside from current levels.

πŸ₯ Steris leads the $21B infection prevention market with diverse medical equipment portfolios.

πŸ’° Q3 revenue hit $1.50B and EPS of $2.53, both beating analyst forecasts.

πŸ“‰ Stock has fallen 27.8% annually, currently trading below key moving averages.

🎯 Analysts rate it a "Moderate Buy" with a $288.43 target implying 34.4% upside.

πŸ₯ STERIS plc (STE) is a $21 billion market cap leader in infection prevention products and services.

πŸ”¬ The company offers a diverse portfolio including sterilizers, surgical tables, and equipment management systems.

πŸ“‰ STE stock slipped 20.4% from its 52-week high of $269.44 reached on Jan. 16.

πŸ“ˆ Over the past three months, STE declined 14.8%, underperforming the Nasdaq Composite's 4.7% losses.

πŸ—“οΈ On a six-month basis, shares fell 14.1%, while over the last year they dipped 27.8%.

πŸ“‰ The stock has traded below its 200-day and 50-day moving averages since early March and February respectively.

πŸ’° STE reported Q3 revenue of $1.50 billion, surpassing analyst estimates of $1.48 billion.

πŸ“Š Adjusted earnings per share reached $2.53, meeting Wall Street forecasts for the quarter.

πŸ” Rival Stryker Corporation (SYK) plummeted 7.4% over 52 weeks but outpaced STE with 12.2% six-month losses.

πŸ‘ Wall Street analysts maintain a "Moderate Buy" consensus rating based on nine analyst opinions.

🎯 The mean price target is set at $288.43, suggesting a potential 34.4% upside from current levels.

Bullish Signals
  • Despite recent stock declines, STERIS plc (STE) reported Q3 revenue of $1.50 billion, surpassing analyst estimates of $1.48 billion.
  • The company's adjusted EPS of $2.53 met Wall Street forecasts, demonstrating solid operational performance relative to expectations.
  • Wall Street analysts maintain a consensus 'Moderate Buy' rating for STE based on positive future prospects.
  • The mean price target of $288.43 suggests a 34.4% potential upside from current price levels according to analyst consensus.
  • STE is valued at $21 billion by market cap, underscoring its size, influence, and dominance within the medical devices industry.
Risk Factors
  • STERIS stock slipped 20.4% from its 52-week high of $269.44 achieved on Jan. 16, indicating significant weakness despite market cap exceeding $21 billion.
  • Over the past three months, STE has declined 14.8%, which is a sharp contrast to the Nasdaq Composite's 4.7% losses during the same period, highlighting underperformance relative to the broader market.
  • On a six-month basis, shares of STE fell 14.1%, while underperforming NASX's six-month marginal losses and significantly trailing the index's 27.8% returns over the last year.
  • The stock has been trading below its 200-day moving average since early March and below its 50-day moving average since early February, confirming a bearish technical trend.
  • STE's rival, Stryker Corporation (SYK), experienced even steeper declines over the past six months with 12.2% losses, but STE still underperformed during that same timeframe with larger drops.